A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. We believe our lead novel and proprietary monoclonal antibody product candidate, DNTH103, has the potential to address a broad array of complement-dependent diseases as currently available therapies and those in development leave room for improvements in efficacy, safety, and/or dosing convenience. We have purposefully engineered DNTH103 to selectively bind to only the active form of the C1s complement protein (“C1s”) and to exhibit improved potency and an extended half-life. By selectively targeting only the active form of C1s, which drives disease pathology and constitutes only a small fraction of the total protein present in circulation, we aim to reduce the amount of drug required for a therapeutic effect.
| Metric | TTM | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Revenue | 8.0M | - | - | 0 | 0 | 0 |
| Net Income | -126M | -85M | -44M | -77M | -58M | -36M |
| EPS | $-3.50 | $-2.55 | $-8.45 | $-2.07 | $-3.13 | $-19.12 |
| Free Cash Flow | 0 | -78M | -37M | -60M | -50M | -24M |
| ROIC | -77.1% | -24.1% | -25.8% | -54.4% | -39.5% | -51.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.06 | 0.06 | 0.14 | 0.08 | -0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -140M | -102M | -48M | -83M | -60M | -36M |
| Operating Margin | -1756.7% | - | - | - | - | - |
| ROE | -23.1% | -32.6% | -25.8% | -53.5% | -39.5% | - |
| Shares Outstanding | 43M | 33M | 32M | 37M | 18M | 33M |
| Metric | 2017 | 2018 | 2019 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | N/A | N/A | 8.0M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -36M | -60M | -83M | -48M | -102M | -140M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | -1756.7% |
| Net Income | -36M | -58M | -77M | -44M | -85M | -126M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -1581.9% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -51.8% | -39.5% | -54.4% | -25.8% | -24.1% | -77.1% |
| ROE | N/A | -39.5% | -53.5% | -25.8% | -32.6% | -23.1% |
| ROA | -65.2% | -36.6% | -48.2% | -24.3% | -30.7% | -21.9% |
| Cash Flow | ||||||
| Op. Cash Flow | -22M | -42M | -57M | -37M | -78M | -110M |
| Free Cash Flow | -24M | -50M | -60M | -37M | -78M | 0 |
| Owner Earnings | -25M | -53M | -69M | -40M | -91M | -123M |
| CapEx | 2.2M | 7.7M | 3.1M | 110K | 105K | 0 |
| Maint. CapEx | 376K | 875K | 1.8M | 67K | 96K | 96K |
| Growth CapEx | 1.8M | 6.8M | 1.2M | 43K | 9K | 0 |
| D&A | 376K | 875K | 1.8M | 67K | 96K | 96K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.3M | 11M | 10M | 2.9M | 13M | 13M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -403M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | 403M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.10 | 0.08 | 0.14 | 0.06 | 0.06 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -42M | 146M | 141M | 169M | 352M | 546M |
| Total Assets | 54M | 157M | 162M | 179M | 374M | 577M |
| Total Liabilities | 4.1M | 12M | 20M | 11M | 22M | 31M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -45M | -103M | -179M | -89M | -174M | -174M |
| Working Capital | 48M | 135M | 136M | 168M | 262M | 262M |
| Current Assets | 53M | 145M | 150M | 177M | 281M | 281M |
| Current Liabilities | 4.1M | 10M | 14M | 9.6M | 18M | 18M |
| Per Share Data | ||||||
| EPS | -19.12 | -3.13 | -2.07 | -8.45 | -2.55 | -3.50 |
| Owner EPS | -0.74 | -2.91 | -1.86 | -1.24 | -2.74 | -2.86 |
| Book Value | -1.26 | 7.91 | 3.81 | 5.26 | 10.58 | 12.74 |
| Cash Flow/Share | -0.67 | -2.28 | -1.54 | -1.15 | -2.35 | -2.94 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 33.5M | 18.4M | 37.1M | 32.1M | 33.3M | 42.9M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -27.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 11.5 | 61.5 | 1.9 | 2.1 | 7.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 509.5 |
| FCF Yield | N/A | -3.0% | -0.7% | -11.4% | -10.3% | N/A |
| Market Cap | N/A | 1.7B | 8.7B | 325M | 758M | 4.1B |
| Avg. Price | N/A | 176.79 | 198.07 | 11.47 | 24.84 | 94.91 |
| Year-End Price | N/A | 91.20 | 234.24 | 10.13 | 22.74 | 94.91 |
Dianthus Therapeutics, Inc. /DE/ passes 0 of 9 quality checks, indicating weak fundamentals.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a 5-year average return on invested capital (ROIC) of -39.1%. This is below average and may indicate limited pricing power.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a market capitalization of $4.1B. It is classified as a mid-cap stock.
Dianthus Therapeutics, Inc. /DE/ (DNTH) does not currently pay a regular dividend.
Dianthus Therapeutics, Inc. /DE/ (DNTH) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Dianthus Therapeutics, Inc. /DE/ (DNTH) generated $-78 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported earnings per share (EPS) of $-2.55 in its most recent fiscal year.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a return on equity (ROE) of -32.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for Dianthus Therapeutics, Inc. /DE/ (DNTH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a book value per share of $10.58, based on its most recent annual SEC filing.
No recent press releases.